Premium
Annexin A6 improves anti‐migratory and anti‐invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells
Author(s) -
Hoque Monira,
Elmaghrabi Yasmin A.,
Köse Meryem,
Beevi Syed S.,
Jose Jaimy,
MenesesSalas Elsa,
BlancoMuñoz Patricia,
Conway James R. W.,
Swarbrick Alexander,
Timpson Paul,
Tebar Francesc,
Enrich Carlos,
Rentero Carles,
Grewal Thomas
Publication year - 2020
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/febs.15186
Subject(s) - a431 cells , cancer research , gefitinib , tyrosine kinase , matrigel , tyrosine phosphorylation , microbiology and biotechnology , mapk/erk pathway , epidermal growth factor receptor , biology , chemistry , signal transduction , cell , receptor , biochemistry , angiogenesis , cell cycle , oncogene
Annexin A6 (AnxA6), a member of the calcium (Ca 2+ ) and membrane binding annexins, is known to stabilize and establish the formation of multifactorial signaling complexes. At the plasma membrane, AnxA6 is a scaffold for protein kinase Cα (PKCα) and GTPase‐activating protein p120GAP to promote downregulation of epidermal growth factor receptor (EGFR) and Ras/mitogen‐activated protein kinase (MAPK) signaling. In human squamous A431 epithelial carcinoma cells, which overexpress EGFR, but lack endogenous AnxA6, restoration of AnxA6 expression (A431‐A6) promotes PKCα‐mediated threonine 654 (T654)–EGFR phosphorylation, which inhibits EGFR tyrosine kinase activity. This is associated with reduced A431‐A6 cell growth, but also decreased migration and invasion in wound healing, matrigel, and organotypic matrices. Here, we show that A431‐A6 cells display reduced EGFR activity in vivo , with xenograft analysis identifying increased pT654‐EGFR levels, but reduced tyrosine EGFR phosphorylation compared to controls. In contrast, PKCα depletion in A431‐A6 tumors is associated with strongly reduced pT654 EGFR levels, yet increased EGFR tyrosine phosphorylation and MAPK activity. Moreover, tyrosine kinase inhibitors (TKIs; gefitinib, erlotinib) more effectively inhibit cell viability, clonogenic growth, and wound healing of A431‐A6 cells compared to controls. Likewise, the ability of AnxA6 to inhibit A431 motility and invasiveness strongly improves TKI efficacy in matrigel invasion assays. This correlates with a greatly reduced invasion of the surrounding matrix of TKI‐treated A431‐A6 when cultured in 3D spheroids. Altogether, these findings implicate that elevated AnxA6 scaffold levels contribute to improve TKI‐mediated inhibition of growth and migration, but also invasive properties in EGFR overexpressing human squamous epithelial carcinoma.